Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | DUT | P33316 | 10/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-Bromouracil SCHEMBL9994785 | 0.85 | SMN1; SMN2 (0.31) | MEN1KMT2A | |
| SCHEMBL294648 | 0.84 | ALDH1A1 (0.49) | ALDH1A1LMNADUTMEN1KMT2A | |
| SCHEMBL873252 | 0.72 | PKM (0.39) | ALDH1A1LMNADUTCRBN | |
| SCHEMBL5792152 | 0.71 | CRBN (0.42) | ALDH1A1LMNADUTCA1CA2 | |
| SCHEMBL20529215 | 0.71 | ALDH1A1 (0.44) | ALDH1A1LMNADUTMEN1KMT2A | |
| Glycine SCHEMBL2322499 | 0.71 | DUT (0.39) | ALDH1A1LMNADUTCRBN | |
| SCHEMBL11581000 | 0.70 | ALDH1A1 (0.43) | ALDH1A1LMNADUTCRBN | |
| SCHEMBL7752441 | 0.69 | PKM (0.38) | ALDH1A1LMNADUTMEN1KMT2A | |
| SCHEMBL2284397 | 0.68 | DBH (0.57) | ALDH1A1DUTMEN1KMT2AKDM4E | |
| SCHEMBL41240 | 0.67 | PKM (0.42) | DUTCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080289-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-10-19 | — | — | EP | claimed |
| EP-2931319-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | claimed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | claimed |
| EP-4370680-A2 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR GENE EXPRESSION REGULATION | Aptah Bio, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023053016-A1 | IONIZABLE CATIONIC COMPOUND | Seqirus Inc. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023288111-A2 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR GENE EXPRESSION REGULATION | APTAH BIO, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-4107782-A1 | MICROARRAYS | Polymer Forge, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-3856228-A1 | METHODS AND PHARMACEUTICAL COMPOSITION REDUCING SKIN INFLAMMATION | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2021-08-04 | — | — | EP | disclosed |
| WO-2021048315-A1 | USE OF DUOX1 INHIBITORS FOR TREATING CANCER | INSTITUT GUSTAVE ROUSSY (FR) | 2021-03-18 | — | — | WO | disclosed |
| WO-2020064907-A1 | METHODS AND PHARMACEUTICAL COMPOSITION REDUCING SKIN INFLAMMATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-04-02 | — | — | WO | disclosed |
| EP-3413927-A1 | CANCER THERAPY | Madison Vaccines Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| EP-1587831-A2 | SPLICED VARIANTS OF LGR6 | Applied Research Systems ARS Holding N.V. (AN) | 2005-10-26 | — | — | EP | disclosed |
| EP-1401999-A4 | B7 RELATED PROTEIN-2 MOLECULES AND USES THEREOF | AMGEN INC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1483384-A2 | METHOD FOR OVEREXPRESSION OF ZWITTERIONIC POLYSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2004058818-A2 | SPLICED VARIANTS OF LGR6 | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-07-15 | — | — | WO | disclosed |
| EP-1401999-A2 | B7 RELATED PROTEIN-2 MOLECULES AND USES THEREOF | Amgen, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003077863-A2 | METHOD FOR OVEREXPRESSION OF ZWITTERIONIC POLYSACCHARIDES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| US-20030056238-A1 | GABA B1A receptor disruptions, compositions and methods relating thereto | DELTAGEN, INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2002097046-A2 | B7 RELATED PROTEIN-2 MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2002-12-05 | — | — | WO | disclosed |